Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.
Can MacroGenics, Inc. (MGNX) Turn Gilead Sciences, Inc. (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
Merck & Co., Inc. (NYSE:MRK): Broad Commercial Footprint Facing a Key Horizon
Merck & Co., Inc. delivered $16.3 billion in total sales for the first quarter of 2026, up 5% year-over-year (3% excluding foreign exchange). Top-line growth continued to be anchored by its flagship oncology therapy, Keytruda, which, alongside its sub-formulations, brought in $8.0 billion in sales, representing an 8% ex-exchange increase. Pulmonary arterial hypertension treatment Winrevair also contributed strongly with $525 million in quarterly revenue, up 87% ex-exchange. GAAP and non-GAAP bottom-line metrics reflected net losses per share of $1.72 and $1.28, respectively, largely driven by upfront charges tied to the strategic acquisition of Cidara Therapeutics. Despite those acquisition-related charges, Merck narrowed and raised the midpoint of its full-year worldwide sales guidance to between $65.8 billion and $67.0 billion.
Merck’s growth story remains heavily reliant on expanding Keytruda’s reach into earlier-stage treatments and novel combination regimens. With key patent expirations approaching toward the end of the decade, management has aggressively pursued business development and combination therapies to diversify its revenue base and maintain its dominance in immuno-oncology.
Gilead Sciences, Inc. (NASDAQ:GILD): Core HIV Strength Drives Outlook
Gilead Sciences, Inc. reported $7.0 billion in total revenue for the first quarter of 2026, posting 5% year-over-year product sales growth. Gilead’s base business, excluding COVID-19 treatment Veklury, rose 8% year-over-year to $6.8 billion, powered by its market-leading HIV franchise, which generated $5.0 billion in sales (up 10% year-over-year). Biktarvy remained the primary growth driver, while newly launched therapies like Yeztugo (lenacapavir) for HIV pre-exposure prophylaxis provided fresh momentum. The corporation’s adjusted diluted earnings per share reached $2.03.
Backed by strong demand across its core virology portfolio, Gilead Sciences, Inc. raised its full-year 2026 total product sales guidance range by $400 million, targeting $30.0 billion to $30.4 billion.
Joint Catalysts: CHMP Recommendation and ISLEND Trial Wins
The complementary strengths of Merck and Gilead were recently put on full display across two key milestones. First, as reported on July 24, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending Gilead’s Trodelvy in combination with Merck’s Keytruda as a first-line treatment for adult patients with unresectable, locally advanced, or metastatic PD-L1–positive triple-negative breast cancer (TNBC). The recommendation, based on robust trial data, pairs Trodelvy’s targeted antibody-drug conjugate (ADC) mechanism with Keytruda’s PD-1 checkpoint inhibition to tackle one of the most aggressive forms of breast cancer.
Simultaneously, the two companies published detailed Phase 3 results from the ISLEND-1 and ISLEND-2 trials on July 21, evaluating an investigational once-weekly single-tablet oral combination of Gilead’s lenacapavir and Merck’s islatravir. The trial data demonstrated high rates of virologic suppression at Week 48, matching standard daily oral antiretroviral regimens like Biktarvy with noninferior efficacy and a favorable safety profile. Positioning this combination as potentially the first once-weekly oral treatment for virologically suppressed adults living with HIV addresses a major hurdle in long-term treatment adherence.
The Bull Case for the Partnership
Combining Gilead’s deep expertise in virology and antibody-drug conjugates with Merck’s clinical and commercial leadership in immuno-oncology creates high-barrier therapeutic moats. A once-weekly oral HIV pill could protect Gilead’s dominance in virology while extending Merck’s footprint in long-acting infectious disease care. In oncology, pairing Trodelvy with Keytruda provides a validated combination in first-line TNBC, expanding Trodelvy’s total addressable market while solidifying Keytruda’s role as the foundational backbone in combination cancer care.
The Bear Case for the Partnership
Regulatory clearances and clinical trial successes do not guarantee seamless commercial execution. In oncology, competitive pressure among antibody-drug conjugates and bispecific antibodies is accelerating, which could limit market adoption if payer coverage is restrictive. In HIV care, transitioning patients from established daily regimens to weekly pills requires overcoming entrenched prescribing habits, while long-term safety monitoring for islatravir remains under scrutiny due to past dosing adjustments in its development cycle. Furthermore, both companies face broader corporate revenue cliff exposure as Keytruda’s loss of exclusivity nears later in the decade.
Insider Monkey’s Hedge Fund Data
According to Insider Monkey’s hedge fund database tracking institutional position changes, hedge fund sentiment diverged between these large-cap pharma names.
For Gilead Sciences, Inc. (NASDAQ:GILD), institutional conviction trended upward, with hedge fund holdings expanding to 77 funds in Q1 2026, up from 71 funds in Q4 2025. Among top institutional holders, Polaris Capital Management, led by Bernard Horn, held 153,300 shares valued at approximately $19.37 million despite trimming its exposure by 40%, representing 1.82% of its total portfolio. Meanwhile, HealthInvest Partners AB, managed by Anders Hallberg and Carl Bennet, maintained a position of 46,142 shares valued at roughly $5.83 million after a minor 4% reduction, making up 1.57% of its portfolio.
By comparison, broader peer Merck & Co., Inc. (NYSE:MRK) experienced a slight pullback in institutional coverage, dropping from 100 hedge fund holdings in Q4 2025 to 98 funds in Q1 2026. Top fund managers showed selective buying: RWC Asset Management, under CEO Tord Stallvik, increased its stake by 2% to 209,086 shares valued at $26.87 million, comprising 1.02% of its overall portfolio. HealthInvest Partners AB demonstrated significant conviction by boosting its Eli Lilly position by 460% to 189,357 shares valued at $24.33 million, bringing the stock to a substantial 6.55% of its total portfolio allocation.
Conclusion
When two biopharma leaders share complementary platforms, collaborative catalysts can unlock growth that neither firm could easily achieve in isolation. Merck & Co., Inc. (NYSE:MRK) gains important pipeline defense against future Keytruda patent cliffs through combination regimens like Trodelvy + Keytruda. Meanwhile, Gilead Sciences, Inc. (NASDAQ:GILD) reinforces its core HIV dominance with a potential first-in-class once-weekly oral option while expanding its oncology footprint. For investors evaluating big pharma, these clinical milestones demonstrate that cross-company alliances are becoming just as vital to driving shareholder value as quarterly financial beats.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.
